Zobrazeno 1 - 10
of 43
pro vyhledávání: '"Kyle B. Stephenson"'
Autor:
A. J. Robert McGray, Ruea-Yea Huang, Sebastiano Battaglia, Cheryl Eppolito, Anthony Miliotto, Kyle B. Stephenson, Amit A. Lugade, Gill Webster, Brian D. Lichty, Mukund Seshadri, Danuta Kozbor, Kunle Odunsi
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-16 (2019)
Abstract Background Cancer immunotherapies are emerging as promising treatment strategies for ovarian cancer patients that experience disease relapse following first line therapy. As such, identifying strategies to bolster anti-tumor immunity and lim
Externí odkaz:
https://doaj.org/article/80478d4009594eabbb5adee11254fa6a
Autor:
Matthew J. Atherton, Laura Evgin, Brian A. Keller, Mira M. Shenouda, Kyle B. Stephenson, Richard G. Vile, John C. Bell, David H. Evans, Brian D. Lichty
Publikováno v:
Molecular Therapy: Oncolytics, Vol 7, Iss , Pp 12-16 (2017)
The 10th International Conference on Replicating Oncolytic Virus Therapeutics was held in Vancouver, Canada from October 1–4, 2016. The agenda for the meeting comprised lectures from several streams within the field of oncolytic viral therapeutics.
Externí odkaz:
https://doaj.org/article/ee73db01ad6b4d42a2f6f45d3aa5d607
Autor:
Jonathan G. Pol, Sergio A. Acuna, Beta Yadollahi, Nan Tang, Kyle B. Stephenson, Matthew J. Atherton, David Hanwell, Alexander El-Warrak, Alyssa Goldstein, Badru Moloo, Patricia V. Turner, Roberto Lopez, Sandra LaFrance, Carole Evelegh, Galina Denisova, Robin Parsons, Jamie Millar, Gautier Stoll, Chantal G. Martin, Julia Pomoransky, Caroline J. Breitbach, Jonathan L. Bramson, John C. Bell, Yonghong Wan, David F. Stojdl, Brian D. Lichty, J. Andrea McCart
Publikováno v:
OncoImmunology, Vol 8, Iss 1 (2019)
Multiple immunotherapeutics have been approved for cancer patients, however advanced solid tumors are frequently refractory to treatment. We evaluated the safety and immunogenicity of a vaccination approach with multimodal oncolytic potential in non-
Externí odkaz:
https://doaj.org/article/f5c2df9bc1ac4874a7e4765ca8f66b01
Autor:
Elena Busch, Kristina D. Kubon, Johanna K. M. Mayer, Gemma Pidelaserra-Martí, Jessica Albert, Birgit Hoyler, Johannes P. W. Heidbuechel, Kyle B. Stephenson, Brian D. Lichty, Wolfram Osen, Stefan B. Eichmüller, Dirk Jäger, Guy Ungerechts, Christine E. Engeland
Publikováno v:
Viruses, Vol 12, Iss 2, p 242 (2020)
Priming and activation of CD8+ T cell responses is crucial to achieve anti-viral and anti-tumor immunity. Live attenuated measles vaccine strains have been used successfully for immunization for decades and are currently investigated in trials of onc
Externí odkaz:
https://doaj.org/article/9af18000f98945f6b2fe4a914b25707b
Autor:
Matthew J. Atherton, Kyle B. Stephenson, Fanny Tzelepis, David Bakhshinyan, Jake K. Nikota, Hwan Hee Son, Anna Jirovec, Charles Lefebvre, Anna Dvorkin-Gheva, Ali A. Ashkar, Yonghong Wan, David F. Stojdl, Eric C. Belanger, Rodney H. Breau, John C. Bell, Fred Saad, Sheila K. Singh, Jean-Simone Diallo, Brian D. Lichty
Publikováno v:
OncoImmunology, Vol 7, Iss 7 (2018)
Prostate cancer (PCa) was estimated to have the second highest global incidence rate for male non-skin tumors and is the fifth most deadly in men thus mandating the need for novel treatment options. MG1-Maraba is a potent and versatile oncolytic viru
Externí odkaz:
https://doaj.org/article/44bc5ab425ff4979b88e6403354f4852
Autor:
Guido Kroemer, AJ Robert McGray, Brian D Lichty, Byram W Bridle, Samuel T Workenhe, Jonathan G Pol, Yonghong Wan, Matthew J Atherton, Kyle B Stephenson, Natasha Kazdhan
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 2 (2020)
Despite a sizeable body of research, the efficacy of therapeutic cancer vaccines remains limited when applied as sole agents. By using a prime:boost approach involving two viral cancer vaccines, we were able to generate large tumor-specific CD8+ T-ce
Externí odkaz:
https://doaj.org/article/745a8aaa49a74933957a9c308438cb2f
Autor:
Brian D. Lichty, Yonghong Wan, Jim Dimitroulakos, Jean-Simon Diallo, Patrick J. Villeneuve, Stephanie Johnson-Obaseki, Lan Chen, Andrew Nguyen, Anna Dvorkin-Gheva, Jake K. Nikota, David F. Stojdl, Charles Lefebvre, Fuan Wang, Jonathan Pol, Kyle B. Stephenson, Matthew J. Atherton
The viral-transforming proteins E6 and E7 make human papillomavirus–positive (HPV+) malignancies an attractive target for cancer immunotherapy. However, therapeutic vaccination exerts limited efficacy in the setting of advanced disease. We designed
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::004a25a427aaa5e64e2a182de6d996b3
https://doi.org/10.1158/2326-6066.c.6548717.v1
https://doi.org/10.1158/2326-6066.c.6548717.v1
Autor:
Brian D. Lichty, Yonghong Wan, Jim Dimitroulakos, Jean-Simon Diallo, Patrick J. Villeneuve, Stephanie Johnson-Obaseki, Lan Chen, Andrew Nguyen, Anna Dvorkin-Gheva, Jake K. Nikota, David F. Stojdl, Charles Lefebvre, Fuan Wang, Jonathan Pol, Kyle B. Stephenson, Matthew J. Atherton
S1: RT-PCR confirms expression of E6 and E7 in TC1 S2: CD4+ T cell responses after E6E7 vaccination S3: E6E7 vaccination induces T-cell degranulation Tumor free S4: Tumor volume curves in E6E7 vaccinated mice S5: TCM frequency in mice after TC1 tumor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7a1d37374edd1e56cb49e62fbf2b9714
https://doi.org/10.1158/2326-6066.22538228.v1
https://doi.org/10.1158/2326-6066.22538228.v1
Autor:
Rebecca C. Auer, C. T. de Souza, Nikolas T. Martin, Amelia Sadie Aitken, John C. Bell, Marie-Claude Bourgeois-Daigneault, K. Geoffroy, Brian D. Lichty, D. Bobbala, J. Kmiecik, Kyle B Stephenson, David F. Stojdl, Dominic G. Roy, Monique Marguerie, Sarwat T. Khan
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-11 (2021)
By conferring systemic protection and durable benefits, cancer immunotherapies are emerging as long-term solutions for cancer treatment. One such approach that is currently undergoing clinical testing is a therapeutic anti-cancer vaccine that uses tw
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::47dacfbaf105a413b9c8dc5347f46b2c
https://doaj.org/article/0087d0d0e932497c868d4c3d99452a6d
https://doaj.org/article/0087d0d0e932497c868d4c3d99452a6d
Autor:
Jonathan L. Bramson, Donald Bastin, Yonghong Wan, Brian D. Lichty, Boris Simovic, Talveer S Mandur, Lan Chen, Scott R. Walsh, Andrew Nguyen, Kyle B Stephenson
Publikováno v:
Journal of Clinical Investigation. 129:5400-5410
While the outcome of adoptive T cell therapy (ACT) is typically correlated with the functionality of the inoculated T cells, the role of the endogenous T cells is unknown. The success of checkpoint blockade therapy has demonstrated the potentially cu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a7435009c4cb8189ef6e32902a66ba8d
https://doi.org/10.1172/jci126199
https://doi.org/10.1172/jci126199